Adopting a healthier lifestyle and losing excess weight is a common resolution for the New Year. Some stick to their resolutions and some don’t, but there are also those who can’t. This month, Dr Nicola Davies shines a light on pro-opiomelanocortin (POMC) deficiency.
Our brain has circuits devoted entirely to telling us when to start and stop eating. Rarely, people carry mutations in certain genes that regulate the function of these fine neuronal circuits. One of these genes, POMC, encodes for pro-opiomelanocortin, a polypeptide that once produced is further processed to several other biologically active peptides. These peptides are involved in various physiologic processes, including appetite regulation, sexual behavior, adrenal steroidogenesis, and skin pigmentation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze